Investors

Share Information

Number of shares: 35,400,873

Total number of outstanding warrants: 16,719,205 (see below for details)

Main terms of warrants as amended (regarding exercise prices) on May 23, 2019:

Warrant

Exercise price/share

Maximum amount of warrants

Expiry date

CBF1

EUR 4.94

12,629 shares

August 18, 2020

CBF2

EUR 2.90

21,513 shares

September 22, 2020

CBF3

EUR 1.95

34,231 shares

October 20, 2020

CBF4

EUR 1.76

74,384 shares

November 8, 2020

CBF5

EUR 1.68

148,769 shares

November 16, 2020

CBF6

EUR 1.60

334,462 shares

December 5, 2020

SEDA1

EUR 3.80

16,094 shares

November 1, 2019

SEDA2

EUR 3.80

26,034 shares

November 11, 2019

SEDA3

EUR 3.80

28,452 shares

November 17, 2019

SEDA4

EUR 3.80

47,940 shares

November 28, 2019

SEDA5

EUR 3.80

25,744 shares

January 17, 2020

SEDA6

EUR 3.80

195,851 shares

March 8, 2020

SITRA1

EUR 3.80

8,388 shares

August 22, 2019

SITRA2

EUR 3.80

27,222 shares

December 5, 2019

SITRA3

EUR 3.80

41,122 shares

March 14, 2020

SITRA4

EUR 3.80

17,211 shares

June 6, 2020

KREOS

EUR 1.60

57,992 shares

July 13, 2022

2019 OFFER WARRANTS 

EUR 0.115*

15,601,167 shares

November 4, 2019

 

* The share subscription price is determined by the volume weighted average price of the Company's share on First North Finland between 7 October 2019 and 18 October 2019, with an applied discount of 25 per cent, the subscription price being, however, at least EUR 0.115 per share. The subscription period for shares subscribed against the Offer Warrants is 22 October - 4 November 2019.

 

Main terms of warrants prior to amendment of the exercise prices on May 23, 2019:

Warrant

Exercise price/share

Maximum amount of warrants

Expiry date

CBF1

EUR 25.62

12,629 shares

August 18, 2020

CBF2

EUR 15.04

21,513 shares

September 22, 2020

CBF3

EUR 10.14

34,231 shares

October 20, 2020

CBF4

EUR 9.11

74,384 shares

November 8, 2020

CBF5

EUR 8.70

148,769 shares

November 16, 2020

CBF6

EUR 8.32

334,462 shares

December 5, 2020

SEDA1

EUR 19.71

16,094 shares

November 1, 2019

SEDA2

EUR 19.71

26,034 shares

November 11, 2019

SEDA3

EUR 19.71

28,452 shares

November 17, 2019

SEDA4

EUR 19.71

47,940 shares

November 28, 2019

SEDA5

EUR 19.71

25,744 shares

January 17, 2020

SEDA6

EUR 19.71

195,851 shares

March 8, 2020

SITRA1

EUR 19.71

8,388 shares

August 22, 2019

SITRA2

EUR 19.71

27,222 shares

December 5, 2019

SITRA3

EUR 19.71

41,122 shares

March 14, 2020

SITRA4

EUR 19.71

17,211 shares

June 6, 2020

KREOS

EUR 8.28

57,992 shares

July 13, 2022

2019 OFFER WARRANTS 

EUR 0.115*

15,601,167 shares

November 4, 2019

 

* The share subscription price is determined by the volume weighted average price of the Company's share on First North Finland between 7 October 2019 and 18 October 2019, with an applied discount of 25 per cent, the subscription price being, however, at least EUR 0.115 per share. The subscription period for shares subscribed against the Offer Warrants is 22 October - 4 November 2019.


Stock option plans total: 330,040 (see below for details)

Option scheme

Subscription price/share

Maximum amount of option rights

Subscription period

2013A

EUR 0.30

1,721 shares

 1.12.2013-31.12.2020

2016B

EUR 4.80

94,191 shares

 1.7.2019-15.12.2024

2016C

EUR 6.00

121,513 shares

1.7.2020-15.12.2025**

2017

EUR 4.80

39,285 shares

 20.10.2018-31.3.2023

2018A

EUR 0.56

36,665 shares

1.7.2022-15.12.2027

2018B

***

36,665 shares

1.7.2023-15.12.2028

** 67,048 stock options of the stock options 2016C have been amended in such way that the first possible share subscription date is July 1, 2021.

*** The share subscription price for stock options 2018B is the trade volume weighted average quotation of the share on Nasdaq Helsinki Ltd during twenty (20) trading days following the release date of the company’s Financial Statements of the year 2019.

Board of Directors authorizations outstanding total: 22,257,465 shares (see below for more details)

The 21 November 2018 Extraordinary General Meeting (EGM) authorised the Board of Directors to decide to issue 7,000,000 new shares either against payment or without consideration.

The new shares may be issued to the Company's shareholders in proportion to their current shareholdings in the Company or deviating from the shareholders' pre-emptive right through one or more directed share issue, if the Company has a weighty financial reason to do so, such as developing the Company's equity structure, implementing mergers and acquisitions or other restructuring measures aimed at developing the Company's business, financing of investments and operations or using the shares as a part of the Company's remuneration and compensation system. The Board of Directors would decide upon terms and scope related to share issues.

Based on the authorisation, the Board of Directors can pursuant to chapter 10, section 1, of the Companies Act also decide on issuing option rights or other special rights entitling to new shares of the Company.

The subscription price of the new shares can be recorded partly or fully to the invested unrestricted equity reserve or to share capital according to the decision of the Board of Directors.

The Board of Directors is entitled to decide on conditions regarding the issuance of shares as well as the issuance of option rights or other special rights entitling to shares.

The authorisation is valid for one year from the EGM. Remaining amount of the authorized amount: 6,060,996 shares.

 

The 25 March 2019 Annual general meeting of shareholders resolved to authorize the board of directors to decide on new share issues as well as issue of option rights and other special rights entitling to shares, pursuant to Chapter 10 of the Companies Act as follows:

In issue(s) of new ordinary shares, the shareholders have the right to subscribe for new shares in proportion to their existing holdings of the shares of the Company. The Board of Directors has the right to decide upon the offering to parties determined by the Board of Directors of any shares that may remain unsubscribed for pursuant to the shareholders' pre-emptive subscription right. In connection with such issue of new ordinary shares, the Board of Directors is authorized to resolve on a directed issue of option rights or the special rights entitling to shares in deviation from the shareholders' pre-emptive right, provided that there is a weighty financial reason for the Company to do so.

Under the authorization, a maximum of sixty three million (63 000 000) shares may be issued in the Share Issue, which corresponds to approximately 95,09 percent of all the shares in the Company after the Share Issue. The ordinary shares and option rights or other special rights entitling to shares can be issued in one or more tranches.

The Board of Directors is authorized to resolve on all terms for the Share Issue.

The Share Issue authorization of the Board of Directors shall be in force for one (1) year from the decision of the Annual General Meeting of Shareholders and it does not revoke the share issue authorization given by the Extraordinary General Meeting on 21 November 2018.

The Company intends to use this authorization for future financing needs and other corporate purposes. Remaining amount of the authorized amount: 16,196,469 shares.

 

All above share information last updated at 20 May 2019.

Terms and conditions for the stock options